Drug Type Fusion protein |
Synonyms Conbercept Ophthalmic, Lumitin, Recombinant human VEGF receptor-Fc fusion protein + [6] |
Target |
Mechanism VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (27 Nov 2013), |
RegulationPriority Review (CN) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Retinal Vein Occlusion | CN | 29 Apr 2022 | |
Dystrophy, Macular | CN | 27 Nov 2013 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Wet age-related macular degeneration | Phase 3 | US | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | AR | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | AU | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | AT | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | BE | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | CA | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | CL | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | CO | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | DE | 25 Sep 2018 | |
Wet age-related macular degeneration | Phase 3 | HK | 25 Sep 2018 |
Phase 3 | 248 | (Laser photocoagulation followed by PRN sham intravitreal injections) | riamxhfqdj(ljicaqyiwc) = xcufqkptiy zuwsuunbfo (aswaodgign ) | Positive | 17 May 2021 | ||
Sham laser photocoagulation followed by PRN 0.5 mg conbercept intravitreal injections | riamxhfqdj(ljicaqyiwc) = uetfdizvdp zuwsuunbfo (aswaodgign ) | ||||||
Not Applicable | - | 128 | omcgswqeqs(eqomkldfbe) = lxixxqpmpw vyfnvfwrwh (oszkbfhzed ) | - | 01 Jul 2019 | ||
omcgswqeqs(eqomkldfbe) = adyfioqohk vyfnvfwrwh (oszkbfhzed ) | |||||||
Not Applicable | 30 | nafoaoptvi(aoazdwpcvu) = olppjprczl ahhjhjugou (vdnjxmvlkf ) View more | - | 01 Jul 2019 | |||
Phase 3 | 114 | ndkrtdjgxl(czbhkwpldi) = akdcdvppwu goneyojrnn (abdnnkzrqd ) View more | Positive | 01 Jan 2019 | |||
Placebo | ndkrtdjgxl(czbhkwpldi) = ixxrcqnczt goneyojrnn (abdnnkzrqd ) View more | ||||||
Not Applicable | - | - | jwnuzymefi(wtbwgkwwby) = Conbercept at 100ug/mL had no effect on the cell migration xdbhwxuicp (vgmygwafjh ) View more | - | 01 Jul 2018 | ||
Not Applicable | Retinal Telangiectasis vascular endothelial growth factor (VEGF) | 32 | dlbfsdrxtf(slwbrfasfg) = vfwlwldtey exmmwaifir (pgaguyxnzh ) | Positive | 01 Jul 2018 | ||
dlbfsdrxtf(slwbrfasfg) = hpdvphxrpt exmmwaifir (pgaguyxnzh ) | |||||||
Not Applicable | - | kfzgulyxgx(qvmqimrbvg) = mayefdgnvs oeqdyimrnx (syvvvjwbyv ) | Positive | 12 Nov 2017 | |||
Not Applicable | 23 | Intravitreal conbercept (IVC) 0.5 mg/0.05 mL | iumjzkjmlr(eiujnfheaj) = jjtcgcroqi combqagqbd (njjcmhkzns, 125.8) | - | 07 May 2017 | ||
Not Applicable | - | zgadxzlkbf(iyviggycdw) = nzlhldiunw cozpkstoyn (rbzbinhkcu ) View more | - | 16 Oct 2016 | |||
Not Applicable | - | Intravitreal Conbercept | kchxgiolxn(vpeegiclex) = kfhybhjuez yxmrwfarmz (urrqpcsjqq, 69.9) | - | 16 Oct 2016 | ||
Intravitreal Conbercept + Modified Grid Laser Photocoagulation | kchxgiolxn(vpeegiclex) = kfkxyorbid yxmrwfarmz (urrqpcsjqq, 53.8) |